A Phase II Study Of Depsipeptide In Patients With Relapsed Or Refractory Ovarian Carcinoma

Trial Profile

A Phase II Study Of Depsipeptide In Patients With Relapsed Or Refractory Ovarian Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Status changed from completed to suspended as reported by ClinicalTrials.gov.
    • 23 Jul 2008 Inclusion exclusion criteria added from NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top